Your Pizza Hut delivery could one day arrive via a self-driving Toyota van.
Toyota unveiled a concept vehicle called e-Palette, which could host a mobile store, act as a ride-sharing service or deliver packages. The announcement was unveiled at International CES in Las Vegas on Monday.
The automaker said it is teaming up with a handful of partners, including Pizza Hut, Amazon, Chinese ridesharing giant Didi and Uber.
“Today, you have to travel to the stores,” Toyota president Akio Toyoda said at the event. “In the future with e-Pallete, the store will come to you.”
Although e-Palette is only a concept vehicle for now, he added that the company plans to pilot the technology at the 2020 Olympic Games in Tokyo. Tests in the U.S. and other areas are envisioned for the early 2020s.
Introducing the first Pizza Hut fully autonomous delivery concept vehicle. Excited for our future with @Toyota #CES2018 pic.twitter.com/YGNQUgijha
Top 10 Stocks To Watch For 2018: Valeant Pharmaceuticals International Inc(VRX)
- [By Chris Lange]
Valeant Pharmaceuticals International Inc. (NYSE: VRX) sawits shares hit a multiyear low this past week. There was hope for a turnaround when Joe Papa took over as chief executive officer,but it seems that littlehas gone his way, especially after the company reported earnings early this week. Some analysts took this opportunity to reevaluate their stance on the stock. Although this might be a buy for some, the returns look to be getting smaller.
- [By Paul Ausick]
Valeant Pharmaceuticals International Inc. (NYSE: VRX) dropped about 6.2% Friday, to post a new 52-week low of $12.90 after closing at $13.75 on Thursday. The stock’s 52-week high is $70.43. Volume was about double the daily average of around 15.9 million shares. The company completed the sale of some skincare brands to L’Or茅al.
- [By Chris Lange]
Valeant Pharmaceuticals International Inc. (NYSE: VRX) made waves early on Tuesday after the company offered a plethora of announcements. First the company gave an update on its late-stage psoriasis trial. Along with this success, Valeant reported the sale of a couple of its business segments, bringing in a sizable amount of cash.
- [By Kumar Abhishek] Valeant Pharmaceuticals(NYSE:VRX) stock jumps after the company sold Dendreon for hefty gains.
Shares of Valeant (NYSE:VRX) jumped more than 14% in pre-market trading yesterday, after the Canadian drug maker announced its long-awaited asset sale plans. The stock later gave away some of its gains after Moody’s released a report stating that the asset sales will not impact its credit rating or outlook, though Valeant’s bond prices jumped by 4.5%. Valeant is a classic example of a shareholder value destroyer. Once the darling of Wall Street, the stock has lost more than 90% of its value since its peak in 2014 and is down by more 80% in the last one year. The stock has dragged portfolios of the likes of Bill Ackman and Prof. Aswath Damodaran. However, the asset saleprovides a ray of hope for Valeant’s shareholders.
- [By WWW.THESTREET.COM]
Bond prices were much lower early in the day, with yields up by nearly 10 basis points. But fixed income has rallied back (reducing the drop by half on the day). Valeant Pharmaceuticals (VRX) , more weakness. Large pharma lower, led by Eli Lilly (LLY) . Old tech lags, with International Business Machines (IBM) , Intel (INTC) , Cisco Systems (CSCO) and Microsoft (MSFT) all lower. Media roughed up a bit (CBS (CBS) and Comcast (CMCSA) ). The Ugly
Gold down another $23 to $1,188 (SPDR Gold Trust ETF (GLD) down $2.25). Urban Outfitters (URBN) down $5. NOTE: There will be no “Takeaways” today! Happy Thanksgiving. Position: Long GLD small, SDS large, JCP large; short SPY, CSCO, CAT small, IWM, TLT small.
- [By Wayne Duggan]
Market laggards that could come under additional window dressing selling pressure include Valeant Pharmaceuticals Intl Inc (NYSE: VRX), Endo International plc – Ordinary Shares (NASDAQ: ENDP) and NewLink Genetics Corp (NASDAQ: NLNK).
Top 10 Stocks To Watch For 2018: CVR Refining, LP(CVRR)
- [By Tyler Crowe]
For refiners, though, that spread in price led to very lucrative refining margins. As that spread has narrowed, so too has margins for refiners.
Refining Margins Q4 2012 Q2 2013
Valero (NYSE: VLO ) $12.27 $9.26
Phillips 66 (NYSE: PSX ) $13.67 $9.88
HollyFrontier (NYSE: HFC ) $24.00 $20.28
CVR Refining (NYSE: CVRR ) $28.08 $20.30
Source: Company Earnings releases
- [By Robert Rapier]
CVR Partners’ fertilizer plant is located in Coffeyville, Kansas, adjacent to the refinery owned by CVR Refining (NYSE: CVRR). CVR Energy (NYSE: CVI), majority-owned by Carl Icahn via Icahn Enterprises (NYSE: IEP), is the general partner and owns most of the units for both CVR Partners and CVR Refining.
- [By Lisa Levin]
Shares of CVR Refining LP (NYSE: CVRR) were down 11 percent to $10.00. Velocity Midstream Partners and CVR Refining disclosed the execution of agreements related to the construction of a crude oil pipeline from the SCOOP play in Central Oklahoma to CVR's Wynnewood refinery.
Top 10 Stocks To Watch For 2018: Euro/Yen(EJ)
- [By Belinda Cao]
E-House China Holdings Ltd. (EJ), a real estate brokerage, gained 9.2 percent to $9.70, extending it advance to a third week. Its American depositary receipts retreated 3.1 percent Sept. 20 from the highest level since May 2011.
Top 10 Stocks To Watch For 2018: Brink's Company (The)(BCO)
- [By Benzinga News Desk]
World Wrestling Entertainment (NYSE: WW) received a pair of downgrades after its earnings report came in below estimates.
Sell-Side's Most Noteworthy Calls
Baird downgraded Cardinal Health (NYSE: CAH) to Neutral.
Imperial downgraded Brinks (NYSE: BCO) to In-Line.
Jefferies upgraded AK Steel (NYSE: AKS) to Buy.
Craig-Hallum upgraded LendingClub (NYSE: LC) to Buy.
General Electric (NYSE: GE) was said to be in talks to acquire Baker Hughes (NYSE: BHI), according to sources as reported by Dow Jones. A deal could be valued at as much as $30 billion. However, Bloomberg later reported that a GE spokesperson said they're in talks with Baker Hughes regarding possible partnerships, but not an acquisition. Halliburton (NYSE: HAL) had attempted to acquire Baker Hughes in 2014, but the DoJ sued to block the deal valued at $35 billion.
- [By Lee Jackson]
Another hedge fund that is also a director at Brink’s Co. (NYSE: BCO) was busy selling stock this past week. Starboard parted with a total of 650,000 shares of the security and protection company at prices that fell between $51.47 and $52.05. The total for the sale was set at $34 million. Shares closed on Friday at $52.00. The consensus price target is $56, and the52-week range is $26.86 to $53.90.
Top 10 Stocks To Watch For 2018: Axsome Therapeutics, Inc.(AXSM)
- [By Lisa Levin]
Axsome Therapeutics Inc (NASDAQ: AXSM) shares dropped 18 percent to $3.62. Axsome Therapeutics priced 3.74 million shares at $3.74 per share.
Shares of Canadian Solar Inc. (NASDAQ: CSIQ) were down around 11 percent to $12.10 after the company posted downbeat quarterly earnings and issued a weak forecast.
- [By William Romov]
Currently trading at $4.85, Manhattan-based Axsome Therapeutics Inc. (Nasdaq: AXSM) makes drugs to treat depression, Alzheimer’s disease, and chronic pain.
- [By Jim Robertson]
On Tuesday, ourUnder the Radar Moversnewsletter suggested shorting small cap clinical-stage biopharmaceutical stock Axsome Therapeutics (NASDAQ: AXSM):
- [By Paul Ausick]
Axsome Therapeutics Inc. (NASDAQ: AXSM) traded down about 43% Tuesday and posted a new 52-week low of $3.20 after closing Monday at $5.55. The 52-week high is $6.45. Volume was about 3.8 million, about 19 times the daily average of around 220,000 shares. The company will stop a “futile” portion of a trial of its treatment for knee osteoarthritis.
Top 10 Stocks To Watch For 2018: Luby's, Inc.(LUB)
- [By Monica Gerson]
Luby’s, Inc. (NYSE: LUB) is expected to post earnings for the latest quarter.
Simulations Plus, Inc. (NASDAQ: SLP) is estimated to post its quarterly earnings at $0.07 per share on revenue of $5.00 million.
Top 10 Stocks To Watch For 2018: Nu Skin Enterprises Inc.(NUS)
- [By Craig Jones]
Nu Skin Enterprises, Inc. (NYSE: NUS) is trading sharply higher on Friday, but options traders are buying puts in the name, said Jon Najarian. Traders were buying the June 50 puts and they paid around 6 percent for them, so they don't see much upside in Nu Skin Enterprises, explained Najarian. He followed the trade and he is planning to hold the position for a month.
- [By Roberto Pedone]
Nu Skin Enterprises (NUS) is a direct selling company, which develops and distributes personal care products and nutritional supplements that are sold under the Nu Skin and Pharmanex brands. This stock closed up 5.4% at $92.96 in Monday’s trading session.
Monday’s Volume: 2 million
Three-Month Average Volume: 900,802
Volume % Change: 85%
From a technical perspective, NUS ripped higher here right above some near-term support at $85 with heavy upside volume. This move pushed shares of NUS into breakout and new 52-week-high territory, since the stock took out some near-term overhead resistance levels at $88.20 to $89.69. This move also pushed shares of NUS above the upper-end of its recent range that saw the stock trend between $82 to just above $89.
Traders should now look for long-biased trades in NUS as long as it’s trending above support at $85 and then once it sustains a move or close above Monday’s high of $93.33 with volume that this near or above 900,802 shares. If we get that move soon, then NUS will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that move are $100 to $105.
- [By Scott Rubin]
Stock gainers included Mercadolibre Inc (NASDAQ: MELI), up almost 14 percent, and Nu Skin Enterprises, Inc. (NYSE: NUS), which added 12 percent. The positive gains in both stocks were due to strong earnings reports. Shares of Liberty Interactive Group (NASDAQ: QVCA) plunged almost 22 percent on Friday due to disappointing sales growth in its fiscal second quarter. Pharmaceutical giant Bristol-Myers Squibb Co (NYSE: BMY) lost 16 percent after a disappointing study involving its Opdivo drug.
- [By Ben Levisohn]
Citigroup’s Beth Kite calls Nu Skin Enterprises’ (NUS) earnings and guidance “awfully disappointing.” She explains why:
“Frustrating” Describes 4Q15 & 2016 Guidance:Nu Skin (i) reported 4Q15 EPS of $0.62, 11 cents below consensus and us, and (ii) lowered 2016 EPS guidance, from $3.25-$3.40 to $2.40-$2.60.Nu Skin had three LTO’s in 4Q152 succeeded and 1 failed. The failure had far less to do with the product than with the sales strategy…
Is Guidance Too Conservative or Is It Really This Bad? We get that Me failed to sell well in South Korea with the 12-month cartridge commitment. But given the strength in reps globally, the strength of Youth from its two LTOs in 2H15, and good results from Me when sold in Japan without the 12-month commitment, we wonder if guidance is aggressive to the downside. Indeed, the word “conservative” was said a lot by mgmt on the brief earnings call when describing guidance revisions.
Maintaining Buy: While we now have less confidence in mgmt, from an external perspective, to forecast its results accurately, and from an internal perspective, to course correct quicklyi.e., why didn’t they drop the 12-month plan for Me in South Korea when it so obviously wasn’t workingwe are still confident in Youth & Me. The rep growth in South Asia/Pacific from Youth in 3Q led to better 4Q sales than we’d expected, Youth’s Americas LTO in 4Q drove lc sales up 26% YoY, and Me not only sold through in Japan in 4Q but also drove reps higher. We imagine that investors may have little patience or confidence in Nu Skin for a while, understandably. But the bar seems set fairly low now, so we are cautiously optimistic that Nu Skin can dig itself out of this hole as we go through 2016 and Me & Youth roll out more fully.
Shares of Nu Skin have tumbled 13% to $27.31 at 2:11 p.m. today.
Top 10 Stocks To Watch For 2018: Oak Valley Bancorp (CA)(OVLY)
- [By Lisa Levin]
In trading on Tuesday, financial shares fell 0.32 percent. Meanwhile, top losers in the sector included Oak Valley Bancorp (NASDAQ: OVLY), down 7 percent, and AmTrust Financial Services Inc (NASDAQ: AFSI) down 5 percent.
Top 10 Stocks To Watch For 2018: Corbus Pharmaceuticals Holdings, Inc.(CRBP)
- [By Sean Williams]
This rapid growth in legal pot has create quite the demand for marijuana stocks. The seven largest marijuana stocks by market cap have all put on a show over the past couple of years. Here are those seven “green giants” listed with their market caps as of March 17, 2017, along with their trailing one-year total returns.
GW Pharmaceuticals (NASDAQ:GWPH): $3.0 billion, up 64% Canopy Growth Corp. (NASDAQOTH:TWMJF): $904 million, up 259% Aphria (NASDAQOTH:APHQF) $440 million, up 381% Aurora Cannabis (NASDAQOTH:ACBFF): $482 million, up 299% AXIM Biotechnologies (NASDAQOTH:AXIM): $562 million, up 1,720% Corbus Pharmaceuticals (NASDAQ:CRBP): $450 million, up 431% Medical Marijuana (NASDAQOTH:MJNA): $221 million, up 254%
As you can see, these are some hefty valuations — and some exceptionally strong moves higher on the heels of marijuana’s expansion. With the exception of GW Pharmaceuticals, every one of the largest marijuana stocks has at least tripled in value over the trailing 12 months, with cannabinoid-based drug developer AXIM Biotechnologies skyrocketing more than 1,700%!
- [By Keith Speights]
Corbus Pharmaceuticals (NASDAQ:CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus’ share price has soared 550%.
Top 10 Stocks To Watch For 2018: Texas Roadhouse, Inc.(TXRH)
- [By Jon C. Ogg]
Texas Roadhouse Inc. (NASDAQ: TXRH) was raised to Buy from Neutral at BTIG Research.
USG Corp. (NYSE: USG) was reiterated as Hold but the price target was raised to $35 from $29 (versus a $34.23 close) at Jefferies.
- [By Joe Tenebruso]
Fortunately, well-chosen dividend-growth stocks can help you accomplish both of these goals. And with its powerful wealth-building combination of increasing dividend payouts and share-price appreciation, Texas Roadhouse (NASDAQ:TXRH)is one of the best available in the market today.
- [By Teresa Rivas]
Texas Roadhouse(TXRH) tumbled more than 12% on Wednesday as itsfourth-quarter earningsand revenue fell short of expectations.
The restaurant chain said it earned 29 cents a share on revenue of $484.7 million. Analysts were expecting earnings per share of 38 cents on revenue of $497.3 million.
Same-restaurant sales grew 1.2% at company restaurants and 2% at domestic franchises. For the first 55 days of the first quarter, Texas Roadhouse said that same-store sales rose 1.5%.
The company also raised its dividend 10.5% to 21 cents a share.
Some analysts urged investors to keep the faith in the stock.Barclay’s JeffreyBernsteinreiterated an Overweight rating and $47 price target on thestock:
We believe TXRH fundamentals remain best-in-class. That said, the near-term focus remains on directional comps. And not unlike the broader industry, TXRH comps eased significantly to close 2016. Such led to disappointing 4Q16 results from top to bottom. Importantly, while the brand ‘is not immune’ to industry comp headwinds, the relative outperformance to the category was maintained. Looking to 2017, key guidance metrics were reiterated. While questions remain on whether the recent easing of industry comps will persist, we remain comforted by TXRH’s relative outperformance and easing comps as we move through 2017.
Maxim’s Stephen Andersonreiterated a Buy rating, although he took his price target down $4, to $52:
In our view, TXRH is not immune to the broader slowdown in Casual Dining, but we believe the company will emerge stronger than peers in the next few quarters.TXRHs disappointing 4Q16 comp of +1.3% (blended) was pulled down by a rare negative comp month in December (-2.1%), marking the first time this occurred in almost four years. Comps were +3% or better in both October and November, and comps so far in 1Q17 are positive despite a stormy start to the quarter in
- [By Dan Caplinger]
Steakhouse chain Texas Roadhouse (NASDAQ:TXRH) has had to deal with an extremely difficult business environment for restaurant companies, and investors know all too well how tough times can hurt major players in the industry. Last quarter, Texas Roadhouse disappointed investors with sluggish results, and the company wanted to start 2017 on a better footing.
- [By Demitrios Kalogeropoulos]
As for individual stocks, Texas Roadhouse (NASDAQ:TXRH) and Garmin (NASDAQ:GRMN)made large moves following their quarterly earnings announcements.